Potent
Therapeutic
Technology
Asep Inc. has developed a proprietary peptide technology that directly addresses the ineffectiveness of current treatment options by suppressing biofilm regrowth and reducing inflammation.
Peptide Technology
Antibiofilm Activity
Potent activity against all major clinically relevant bacteria growing as antibiotic-resistant biofilms.
Antibiotic Synergy
Work in combination with conventional antibiotics to overcome antibiotic resistance.
Safe and Effective in Animal Infection Models
Work in in vivo models of biofilm infections such as sinusitis and abscesses.
Anti-inflammatory Activity in vivo
As strong as the nonsteroidal anti-inflammatory drug indomethacin.
Immune modulating activity
Suppress harmful inflammation while boosting protective innate immunity.
Combined Activities
Optimized peptides with combined activity profiles for clinical applications.
pre-Clinical DEVELOPMENT
The company is pursuing clinical validation in the treatment of organisms associated with Sinusitis pathogens in a planned study in Vancouver, Canada, along with other development efforts:
In vitro and in vivo anti inflammatory and immunomodulatory activities have been extensively characterized.
Peptides have demonstrated excellent activity profiles in relevant biofilm infection models of sinusitis and infected wounds.
New formulations, initial pharmacokinetics and pharmacodynamics studies have been defined and/or developed.
Fuente-NúñezC, REW Hancock et al. 2014. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathogens 10(5):e1004152; Fuente-Núñez C, REW Hancock et al. 2015. D-enantiomeric peptides that eradicate wild-type and multi-drug resistant bacterial biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem. Biol. 22:196–205; Pletzer, D., S.C. Mansour, and R.E.W. Hancock. 2018. Synergy between conventional antibiotics and anti-biofilm peptides in a murine,sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens. PLoS Pathogens 14(6):e1007084; Reffuveille F, C. REW Hancock et al. 2014. A broad-spectrum anti-biofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob. Agents Chemother. 58:5363-5371; Zhang, T., L.Xia, Z. Wang, R.E.W. Hancock, and M. Haapasalo. 2021. Recovery of oral in vitro biofilms after exposure to peptides and chlorhexidine. J. Endodontics 47:466-471; Alford, M.A., K.-Y.G. Choi, M.J. Trimble, H. Masoudi, P. Kalsi, D. Pletzer, R.E.W. Hancock. 2021. Murine models of sinusitis infection for screening antimicrobial and immunomodulatory therapies. Frontiers Cell. Infect. Microbiol. 11:621081; Wu, B.C., A.H. Lee, and R.E.W. Hancock. 2017. Mechanisms of the innate defense regulator peptide-1002 anti-inflammatory activity in a sterile inflammation mouse model. J. Immunol. 199:3592-3603.
ASEP and its subsidiaries' technologies have not received marketing authorization
and are not currently available for purchase. © 2023 All Rights Reserved